Anthony Loussouarn, Ph.D.
Chief Executive Officer – Co founder
Anthony holds a Doctorate in Life Science and Health from the University of Nantes with a specialization in Radiochemistry and Radiopharmacy. He had two years postdoctoral research training in Australia (Murdoch University, Fremantle Hospital and ANSTO) where he specialized in monoclonal antibodies radiolabelling and Preclinical studies. From 2001 to mid 2005 he was Managing Director of the company before his appointment as President of Chelatec.
Jean-François Gestin, Ph.D.
Business Developer - Co founder
Jean-François obtained his PhD in Chemistry in 1989 after one year at CIS BIO International and two years at the Brookhaven National Laboratory, Upton NY. He joined INSERM Institute in 1990 in order to create and lead the Bioconjugate chemistry research team under leadership of Pr. Jean-François Chatal. He participated to the creation of Chelatec in 2000.
Today, Jean-François is Director of Research at INSERM institute, head of the chemistry and radiochemistry department. He is in charge of the Business Development of Chelatec.
Julien Le Gal, Ph.D.
Project Manager
Julien holds of a PhD in Chemistry and Radiochemistry from the University Paul Sabatier of Toulouse (2004). He performed his research project on the design of new 99mTc radiopharmaceuticals and on their in vivo behavior. He then worked during two years at the CEA/Saclay (Department of molecular engineering of proteins/SIMOPRO) as a post-doctoral fellow on the combinatorial assembly of rhenium and technetium complexes targeting αVβ3 integrins. In October 2006, he joined Chelatec as Project Manager.